SynthesisFrontiers in pediatrics2025
Risk factors for refractory
Synthesis in Frontiers in pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Development and validation of a multivariate predictive model for the risk of refractory mycoplasma pneumoniae pneumonia in children based on quantitative computed tomography features.Translational pediatrics · 2026Article
- Profound immune suppression and exhaustion characterize refractory mycoplasma pneumoniae pneumonia in children.Frontiers in immunology · 2026Article
- Prediction models for refractoryFrontiers in pediatrics · 2026Article
- Development of a nomogram for predicting refractoryTranslational pediatrics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: With the increase of the incidence rate of Methods: This systematic search was conducted in Web of Science, Embase, PubMed, Cochrane Library, CNKI, Wangfang, Sinomed and Cqvip, and the date was set until August 20, 2024. After two researchers independently screened the literature, extracted data, and assessed the risk of bias in the included studies, a meta-analysis was conducted using STATA 17.0 and RevMan 5.4 software. Results: Twenty-eight studies including 6374 patients were included in this analysis, and the results showed that the age [ Conclusion: Our study further confirmed that elevated inflammatory markers such as CRP, LDH, neutrophils (%), IL-6, ESR, lung consolidation, combined pleural effusion were risk factors for RMPP. For the first time, WBC, ALT, and AST were identified as risk factors for the occurrence of RMPP in children. Additionally, demographic information such as age and gender was also examined in relation to RMPP in children.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.